Patents by Inventor Susan M. Freier

Susan M. Freier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for modulating MECP2 expression
    Patent number: 11129844
    Abstract: Disclosed herein are compounds and methods for decreasing MECP2 mRNA and protein expression. Such compounds and methods are useful to treat, prevent, or ameliorate MECP2 associated disorders and syndromes. Such MECP2 associated disorders include MECP2 duplication syndrome.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: September 28, 2021
    Assignees: Ionis Pharmaceuticals, Inc., Baylor College of Medicine
    Inventors: Susan M. Freier, Huda Y. Zoghbi, Ezequiel Sztainberg
  • MODULATION OF LNC05 EXPRESSION
    Publication number: 20210290653
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of lnc05 in a cell or individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a cancer in an individual.
    Type: Application
    Filed: June 3, 2021
    Publication date: September 23, 2021
    Inventors: Allen Tingjin Yu, David L. Spector, Frank Rigo, Susan M. Freier, Jan Bergmann, Carmen Berasain
  • METHODS FOR TREATING HYPERCHOLESTEROLEMIA
    Publication number: 20210285003
    Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.
    Type: Application
    Filed: September 25, 2020
    Publication date: September 16, 2021
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Diane Tribble, Sanjay Bhanot, Andrew T. Watt
  • Modulation of angiopoietin-like 3 expression
    Patent number: 11118183
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids and/or glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease and/or metabolic disease, or a symptom thereof, in an individual in need thereof.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: September 14, 2021
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Mark J. Graham, Rosanne M. Crooke
  • COMPOUNDS AND METHODS FOR MODULATING UBE3A-ATS
    Publication number: 20210277397
    Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of UBE3A-ATS, the endogenous antisense transcript of ubiquitin protein ligase E3A (UBE3A) in a cell or subject, and in certain instances increasing the expression of paternal UBE3A and the amount of UBE3A protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurogenetic disorder. Such symptoms and hallmarks include developmental delays, ataxia, speech impairment, sleep problems, seizures, and EEG abnormalities. Such neurogenetic disorders include Angelman Syndrome.
    Type: Application
    Filed: April 21, 2021
    Publication date: September 9, 2021
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Huynh-Hoa Bui, Paymaan Jafar-nejad, Frank Rigo
  • Compositions and Methods for Modulating PKK Expression
    Publication number: 20210277401
    Abstract: Disclosed herein are antisense compounds and methods for decreasing PKK mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate PKK-associated diseases, disorders, and conditions.
    Type: Application
    Filed: May 11, 2020
    Publication date: September 9, 2021
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Susan M. Freier, Huynh-Hoa Bui
  • Compositions for modulating Ataxin 2 expression
    Patent number: 11111494
    Abstract: Disclosed herein are antisense compounds and methods for decreasing Ataxin 2 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotropic sclerosis (ALS), and parkinsonism.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: September 7, 2021
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventor: Susan M. Freier
  • Compositions and their uses directed to huntingtin
    Patent number: 11072794
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's Disease (HD) progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntington's Disease (HD) in an individual susceptible to Huntington's Disease (HD). Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
    Type: Grant
    Filed: April 15, 2020
    Date of Patent: July 27, 2021
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventor: Susan M. Freier
  • Methods of treating breast cancer
    Patent number: 11058709
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a MaTAR in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate breast cancer in an individual in need.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: July 13, 2021
    Assignees: Ionis Pharmaceuticals, Inc., Cold Spring Harbor Laboratory
    Inventors: David L. Spector, Sarah Daniela Diermeier, Frank Rigo, C. Frank Bennett, Susan M. Freier, Gayatri Arun, Kung-Chi Chang
  • COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION
    Publication number: 20210207146
    Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with excess growth hormone using antisense compounds or oligonucleotides targeted to growth hormone receptor (GHR).
    Type: Application
    Filed: August 4, 2020
    Publication date: July 8, 2021
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Sanjay Bhanot, Susan M. Freier, Huynh-Hoa Bui
  • Modulation of prekallikrein (PKK) expression
    Patent number: 11053500
    Abstract: Disclosed herein are antisense compounds and methods for decreasing PKK mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate PKK-associated diseases, disorders, and conditions.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: July 6, 2021
    Assignee: lonis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Huynh-Hoa Bui
  • MODULATORS OF ENaC EXPRESSION
    Publication number: 20210180057
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting ENaC expression, which may be useful for treating, preventing, or ameliorating a disease associated with ENaC.
    Type: Application
    Filed: October 31, 2018
    Publication date: June 17, 2021
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Jeffrey R. Crosby, Shuling Guo, Huynh-Hoa Bui, Andrew T. Watt, Susan M. Freier
  • Modulation of Lnc05 expression
    Patent number: 11033570
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of Inc05 in a cell or individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a cancer in an individual.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: June 15, 2021
    Assignees: Cold Spring Harbor Laboratory, Ionis Pharmaceuticals, Inc.
    Inventors: Allen Tingjin Yu, David L. Spector, Frank Rigo, Susan M. Freier, Jan Bergmann, Carmen Berasain
  • MODULATION OF FACTOR 11 EXPRESSION
    Publication number: 20210169921
    Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.
    Type: Application
    Filed: July 29, 2020
    Publication date: June 10, 2021
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Chenguang Zhao, Brett P. Monia, Hong Zhang, Jeffrey R. Crosby, Andrew M. Siwkowski
  • MODULATORS OF EZH2 EXPRESSION
    Publication number: 20210155935
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting EZH2 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with EZH2.
    Type: Application
    Filed: April 11, 2019
    Publication date: May 27, 2021
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Minji Jo, Youngsoo Kim, Robert MacLeod, Susan M. Freier
  • Allele specific modulators of P23H rhodopsin
    Patent number: 11013758
    Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, ameliorating, or slowing progression of retinitis pigmentosa (RP), such as autosomal dominant retinitis pigmentosa (AdRP) by administering a P23H rhodopsin specific inhibitor to a subject. The present embodiments provided herein are directed to compounds and compositions useful for treating, preventing, ameliorating, or slowing progression of retinitis pigmentosa (RP), such as autosomal dominant retinitis pigmentosa (AdRP). In certain embodiments, P23H rhodopsin inhibitors provided herein are allele-specific antisense compounds targeted to a P23H mutant allele that are capable of selectively inhibiting expression of P23H rhodopsin mutant protein to a greater extent than wild-type protein.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: May 25, 2021
    Inventors: Susan F. Murray, Punit P. Seth, Michael L. McCaleb, Susan M. Freier, Priyam Singh
  • Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof
    Publication number: 20210147837
    Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.
    Type: Application
    Filed: June 30, 2020
    Publication date: May 20, 2021
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Eric E. Swayze
  • MODULATION OF HUNTINGTIN EXPRESSION
    Publication number: 20210139900
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Application
    Filed: October 12, 2020
    Publication date: May 13, 2021
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • COMPOUNDS AND METHODS FOR REDUCING SPDEF EXPRESSION
    Publication number: 20210139906
    Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of SPDEF RNA in a cell or subject, and in certain instances reducing the amount of SPDEF protein in a cell or subject. These compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a disease or condition characterized by excessive mucus production or fibrosis, including cystic fibrosis, asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), chronic bronchitis, rhinitis and ulcerative colitis.
    Type: Application
    Filed: January 12, 2021
    Publication date: May 13, 2021
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Huynh-Hoa Bui, Shuling Guo, Jeffrey R. Crosby
  • Modulators of PCSK9 expression
    Patent number: 11000595
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting PCSK9 expression, which may be useful for treating, preventing, or ameliorating a disease associated with PCSK9.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: May 11, 2021
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Susan M. Freier, Huynh-Hoa Bui